The FDA has granted Breakthrough Device status to BioVentrix, Inc.’s Revivent TC Transcatheter Ventricular Enhancement System, a proactive approach to treating MI-induced heart failure.

BioVentrix…

A novel pacemaker designed to mimic a patient’s organic breath increased blood flow to the heart in a study of individuals with heart failure, according to research published in the journal…

Patients with heart failure and reduced ejection fraction (HFrEF) are well served by treatment with the glucose-lowering drug dapagliflozin, as it warded off death and hospitalization while also improving…

A collaboration between physicists and cardiologists at the University of California San Diego has resulted in an AI tool that can predict heart failure patients’ life expectancy with 88% accuracy.

UCSD physics…

Results from the world’s largest comprehensive study of hypertrophic cardiomyopathy (HCM) patients are in—and they’re providing cardiologists with a wealth of previously unknown information about the disease.

…

The 2010s saw a decrease in age-adjusted mortality associated with heart disease (HD), according to a JAMA Cardiology report published Oct. 30,…

Research published in JACC: Heart Failure…

Research out of Brigham and Women’s Hospital in Boston found heart failure patients who self-identify as black, Latinx or female are less likely to be admitted to the hospital’s cardiology department, suggesting admission bias might be…

The combo drug sacubitril/valsartan was associated with early improvements in health status in a study of nearly 4,000 patients with heart failure with reduced ejection fraction (HFrEF).

The study, published in the…

Metformin use is linked to a lower risk of hospitalization for heart failure in patients with type 2 diabetes, a paper in the Journal of the American Heart…

A novel machine learning algorithm improved patient selection for cardiac resynchronization therapy (CRT) in a study of nearly 1,000 heart failure patients in the U.S., representing an opportunity to optimize care and spare certain…

Pharmaceutical company AstraZeneca announced Oct. 21 that its drug Farxiga—or dapagliflozin—was approved by the FDA to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.

The FDA has…

Around one in five heart patients in cardiac rehabilitation are depressed, anxious or stressed, according to a new study published in the European Journal of…

Evidence published in BMJ Heart last month supports the idea of an “obesity paradox” in heart failure (HF), further complicating a long-running…

A 90-minute communication skills course improved conversations about implantable cardioverter-defibrillator (ICD) deactivation and goals of care between clinicians and their patients, according to the recently published results of the…

New research suggests the incidence of cardiac amyloidosis in the U.S. is trending up, bringing with it high rates of morbidity and mortality.

Scientists have long assumed the instance of…

Just weeks after it fast-tracked dapagliflozin for the treatment of chronic kidney disease (CKD), the FDA announced it was granting Fast Track status to the drug for another indication: heart failure.

Dapagliflozin,…

Research presented at the ESC Congress in Paris Sept. 2 suggests malaria could be linked to as much as a 30% increased risk of heart failure.

First author Philip Brainin, a postdoctoral research fellow at Herlev-…

Research out of the Netherlands suggests current clinical guidelines might recommend overtreatment for women with heart failure, who see maximum benefit from HF drugs at half the dose of men.  

Drugs like angiotensin-converting…

SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events (MACE).

The scientists who connected the dots—…

Oregon Health & Science University will resume its heart transplant services this month after nearly a year of inactivity, the university announced Aug. 26.

OHSU reported it received a unanimous OK from the United…